Abstract:We report the self‐assembly and anticancer mechanism studies of lithocholic acid conjugated Pt(IV) complex that preferentially accumulates within the mitochondria and mitochondria‐free cytoplasm of prostate cancer cells and inhibit its proliferation via activating multiple cell death pathways. Platinum(IV) prodrugs are highly promising anticancer agents because they can selectively target tumors and minimize the adverse effects associated with their PtII congeners. In this study, we synthesized dual action PtIV complexes by linking oxoplatin with lithocholic acid. The synthesized compounds, designated as PL‐I, PL‐II, and PL‐III, can spontaneously self‐assemble in water, resulting in the formation of spherical shape nanoparticles. Among the developed complexes, PL‐III appeared to be the most potent compound against all the tested cancer cell lines, with 10 fold higher cytotoxicity compared to cisplatin in PC3 cells. The complex arrests the cell cycle in the S and G2 phases and induces DNA damage. Additional mechanistic investigations demonstrate that PL‐III predominantly localizes within the mitochondria and cytoplasm. Consequently, PL‐III disrupts mitochondrial membrane potential, increases ROS production, and perturbs mitochondrial bioenergetics in PC3 cells. The complex induces apoptosis through the mitochondrial pathway by upregulating pro‐apoptotic protein expression and downregulating anti‐apoptotic protein expression from the BCl‐2 protein family. These results demonstrate that higher cellular uptake and reduction of PL‐III by biological reductants in PC3 cells resulted in a synergistic effect of lithocholic acid and cisplatin, which can be easily observed due to its unique cytotoxic mechanism. This further underscores the significance of dual‐action PtIV complexes in enhancing the efficacy of cancer therapy.

Mitochondria-targeting monofunctional platinum(ii)-lonidamine conjugates for cancer cell de-energization

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

Mitochondria-targeted platinum(ii) complexes: dual inhibitory activities on tumor cell proliferation and migration/invasion via intracellular trafficking of β-catenin.

Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.

Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer

Enhancing Cytotoxicity of a Monofunctional Platinum Complex Via a Dual-DNA-Damage Approach.

A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

Mitochondria-targeted Platinum(ii) Complexes Induce Apoptosis-Dependent Autophagic Cell Death Mediated by ER-stress in A549 Cancer Cells

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

A Dual Action Platinum(IV) Complex with Self‐assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin

Dual Mitochondria- and DNA-Targeting Coumarin-Pt(IV) Prodrug for the Enhancement of Anticancer Performance

New Platinum(II) Agent Induces Bimodal Death of Apoptosis and Autophagy Against A549 Cancer Cell.

Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy

Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester As a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.

Coumarin-appended phosphorescent cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.

Highly Potent Platinum(IV) Complexes with Multiple-Bond Ligands Targeting Mitochondria to Overcome Cisplatin Resistance.

Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective PlatinumIV Prodrug Against Triple Negative Breast Cancer.